Literature DB >> 11182222

Investigation of HLA class I downregulation in breast cancer by RT-PCR.

G L Palmisano1, M P Pistillo, P Capanni, C Pera, G Nicolò, S Salvi, L Perdelli, G Pasciucco, G B Ferrara.   

Abstract

Downregulation of HLA class I antigen expression has been reported in a significant proportion of primary breast carcinomas suggesting an escape mechanism from CTL mediated lysis leading to tumor dissemination and metastasis. We have previously reported the biochemical and immunohistochemical analysis of HLA total class I (W6/32 mAb), alpha-chain (Q1/28,TP25.99 mAbs) and beta(2)-microglobulin (Namb-1 mAb) subunits expression in 25 primary breast carcinomas. This study at protein level resulted in the observation of three different HLA class I expression patterns by both techniques: high, low, and absent downregulation patterns. To better characterize the HLA class I antigens downregulation we extended such analysis also at RNA level by RT-PCR using HLA-A, HLA-B, HLA-C, and beta(2)-microglobulin specific primers either in breast cancer or normal tissues derived from the same patient. None (100%) of the alpha-chain genes analyzed in patient tumor tissues showed significant reduction of expression. In 10 patients out of 25 (40%) the beta(2)-microglobulin gene showed complete loss of expression compared with the corresponding normal tissue counterpart, which showed a constitutive expression, whereas in 2 patients (12.5%) its expression was comparable with the normal counterpart. Sequence analysis at genomic level revealed no defects affecting beta(2)-microglobulin gene in those patients showing lack of expression. Also TAP1 and TAP2 genes expression were investigated in order to confirm or exclude involvement of the MHC class I molecules assembling machinery. The RT-PCR approach mainly confirmed our beta(2)-microglobulin biochemical analysis indicating that in breast cancer specimens it is possible to address the HLA class I gene downregulation as a phenomenon occurring at post-transcriptional level mainly affecting the beta(2)-microglobulin gene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11182222     DOI: 10.1016/s0198-8859(00)00241-x

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

1.  Identification of proteins of human colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry.

Authors:  Ying-Tao Zhang; Yi-Ping Geng; Le Zhou; Bao-Chang Lai; Lv-Sheng Si; Yi-Li Wang
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

2.  Association of HLA-G +3142 C>G polymorphism and breast cancer in Tunisian population.

Authors:  Inès Zidi; Olfa Dziri; Nour Zidi; Refaat Sebai; Nadia Boujelebene; Amna Ben Hassine; Hamza Ben Yahia; Ahmed Baligh Laaribi; Wafa Babay; Hela Rifi; Amel Mezlini; Hanene Chelbi
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

3.  Analysis of HLA class Ia transcripts in human leukaemias.

Authors:  Durjoy Majumder; Debasis Bandyopadhyay; Sarmila Chandra; Ashis Mukhopadhayay; Nandini Mukherjee; Subir K Bandyopadhyay; Subrata Banerjee
Journal:  Immunogenetics       Date:  2005-09-29       Impact factor: 2.846

Review 4.  Opportunities and challenges for TCR mimic antibodies in cancer therapy.

Authors:  Aaron Y Chang; Ron S Gejman; Elliott J Brea; Claire Y Oh; Melissa D Mathias; Dmitry Pankov; Emily Casey; Tao Dao; David A Scheinberg
Journal:  Expert Opin Biol Ther       Date:  2016-04-27       Impact factor: 4.388

Review 5.  Tumor immunoediting and immunosculpting pathways to cancer progression.

Authors:  Jennifer M Reiman; Maciej Kmieciak; Masoud H Manjili; Keith L Knutson
Journal:  Semin Cancer Biol       Date:  2007-06-26       Impact factor: 15.707

6.  Single nucleotide variant profiles of viable single circulating tumour cells reveal CTC behaviours in breast cancer.

Authors:  Yipeng Wang; Liping Guo; Lin Feng; Wen Zhang; Ting Xiao; Xuebing Di; Guoji Chen; Kaitai Zhang
Journal:  Oncol Rep       Date:  2018-03-20       Impact factor: 3.906

Review 7.  Opportunities and Challenges for Antibodies against Intracellular Antigens.

Authors:  Xiaofeng Yang; Shenxia Xie; Xiaomei Yang; Juan C Cueva; Xiaoqiong Hou; Zhuoran Tang; Hua Yao; Fengzhen Mo; Shihua Yin; Aiqun Liu; Xiaoling Lu
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

8.  Overexpression of beta2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion.

Authors:  C-H Chen; C-Y Su; C-Y Chien; C-C Huang; H-C Chuang; F-M Fang; H-Y Huang; C-M Chen; S-J Chiou
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

9.  Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells.

Authors:  G L Scheffer; M C de Jong; A Monks; M J Flens; C D Hose; M A Izquierdo; R H Shoemaker; R J Scheper
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.